Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 210

Sort by

Sort Order Select

Journal Articles

Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia

Ying Wang, Qingsong Yin, Jinhai Ren, Hongsheng Zhou, Tiejun Gong, Feng Zhu, Xi Zhang, Qin Wen, Heng Mei, Wei Huang, Zhenghong Chen, Bhargava Kandala, Jingxia Chen, Jianxiang Wang

Blood (2025) 146 (Supplement 1): 647.

https://doi.org/10.1182/blood-2025-647

Published: 2025

Journal Articles

Impact of antibiotic exposure on CAR-T cell therapy outcomes: Analysis in multiple Myeloma and lymphoma

Bin Lv, Lingling Yin, Ying Wang, Weiying Gu, Zhenyu Li, Kailin Xu, Feng Zhu

Blood (2025) 146 (Supplement 1): 4071.

https://doi.org/10.1182/blood-2025-4071

Published: 2025

Journal Articles

Upfront maintenance therapy improves the prognosis of patients with diffuse large B-cell lymphoma in the era of novel agents: A multicenter retrospective study

Liwei Lv, Liu Zixian, Yan-ying Wang, Jie Li, He-Bing Zhou, Li Hong Li, Zhenling Li, Liang Wang

Blood (2025) 146 (Supplement 1): 7227.

https://doi.org/10.1182/blood-2025-7227

Published: 2025

Journal Articles

Clinical features and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia: A 15-year retrospective study

Yiyan Zhu, Wenzhi CAI, Xueqing Dou, Ying Wang, Xiaofei Yang, Haiping Dai, Depei Wu, Suning Chen

Blood (2025) 146 (Supplement 1): 5103.

https://doi.org/10.1182/blood-2025-5103

Published: 2025

Journal Articles

Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy

jiabiao hu, Yanan Yue, tianying chen, lina zhou, xiaomeng Bian, xiaobin song, huan chen, xu feng, yuqing lin, yixuan zhou, yingyong xu, Jianxiang Wang, Ying Wang, george church, Luhan Yang

Blood (2025) 146 (Supplement 1): 1045.

https://doi.org/10.1182/blood-2025-1045

Published: 2025

Journal Articles

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Blood (2025) 146 (Supplement 1): 1042.

https://doi.org/10.1182/blood-2025-1042

Published: 2025

Journal Articles

Synergistic integration of CAR-T cell pharmacokinetics and NGS-MRD evolution enables precision risk stratification in relapsed/refractory B-cell acute lymphoblastic leukemia

Runxia Gu, Shuning Wei, Shaowei Qiu, Xiaoyuan Gong, Guangji Zhang, Benfa Gong, Qiuyun Fang, Shouyun Li, Kaiqi Liu, Dong Lin, Ying Wang, Chunlin Zhou, Bingcheng LIU, Yingchang Mi, Hui Wei, Jianxiang Wang, Ying Wang

Blood (2025) 146 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2025-3366

Published: 2025

Journal Articles

Mitoxantrone liposome, subcutaneous cytarabine and G-CSF (CMG) combined with venetoclax as first-line treatment in secondary Acute Myeloid Leukemia (sAML) or elderly AML patients: A multicenter, prospective, single-arm clinical trial with concurrent control

Xiaoqian Xu, Ying Lu, Weiying Bao, Xiuhua Han, Ran An, Ying Wang, Zhiyin Liu, Jie Tian, Xingying Li, Zeying Yan, Haimin Sun, Li Chen, Sujiang Zhang

Blood (2025) 146 (Supplement 1): 3447.

https://doi.org/10.1182/blood-2025-3447

Published: 2025

Journal Articles

ZFP36L2 as a promising therapeutic target in acute graft-versus-host disease: Evidence from murine models and clinical validation

Li Li, Andie Fu, Xiwen Tong, Bin Xu, Xia Mao, Ying Wang, Shiyuan Zhang, Yi Zhu, Jia Wei, Donghua Zhang

Blood (2025) 146 (Supplement 1): 5863.

https://doi.org/10.1182/blood-2025-5863

Published: 2025

Journal Articles

First-in-human phase I study of HCB101, a 3.5th-generation CD47-SIRPα fc fusion protein: Cytopenia-sparing safety, broad pharmacologic window, and low-dose clinical activity in relapsed/refractory non-Hodgkin lymphoma

Abigail Yu, Wenyu Li, Zhili Zhou, Junjie Li, Charles Wang, Wei Ji, Ying Wang, Jian Zhang, Wei-Hong Cheng, Tian Zhang, Chihyi Hsieh, Alvin Luk, Vivien Zhang, David Sun, Yan Zhang

Blood (2025) 146 (Supplement 1): 3299.

https://doi.org/10.1182/blood-2025-3299

Published: 2025

Journal Articles

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Yong-xian Hu, Xiaoyu Zhu, Heng Mei, Ying Wang, Yali Zhou, Kangqi Bian, Maria del Rosario, Eileen McNulty, Ming Gao, Lu Han, Wengang Ge, Jan Davidson-Moncada, Jiangtao Ren, He Huang

Blood (2025) 146 (Supplement 1): 816.

https://doi.org/10.1182/blood-2025-816

Published: 2025

Journal Articles

Enhanced vsvg variants for binder‑dependent and high‑specificity transduction of primary T cells

kaiyuan wang, xiaoling wang, wancheng yang, Jiapan Hu, yixuan zhou, qi zhang, xuqiang kong, hao wang, peng zhang, yingyong xu, Jianxiang Wang, Ying Wang, Luhan Yang

Blood (2025) 146 (Supplement 1): 4181.

https://doi.org/10.1182/blood-2025-4181

Published: 2025

Journal Articles

Droplet digital PCR outperforms conventional methods for early relapse prediction in AML/MDS patients post-transplant

Xiao Zhou, Ying Wang, Yu Cai, Chongmei Huang, Juan Yang, Huiying Qiu, Yin Tong, Baoxia Dong, Xianmin Song, Liping Wan

Blood (2025) 146 (Supplement 1): 2486.

https://doi.org/10.1182/blood-2025-2486

Published: 2025

Journal Articles

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Blood (2025) 146 (Supplement 1): 5122.

https://doi.org/10.1182/blood-2025-5122

Published: 2025

Journal Articles

Long-term outcomes with emicizumab prophylaxis in patients with hemophilia a in China

Blood (2025) 146 (Supplement 1): 1287.

https://doi.org/10.1182/blood-2025-1287

Published: 2025

Journal Articles

Neutrophil count is an independent prognostic indicator in early T-cell precursor lymphoblastic leukemia

Jieping Lin, Xiaoyuan Gong, Nanfang Zhuo, Chengming He, Yiming Cai, Zhixiang Wang, Xuan Zhou, Bailin He, Wenhao Zhong, Qifa Liu, Suning Chen, Yang Xu, Huafeng Wang, Ying Wang, Hongsheng Zhou

Blood (2025) 146 (Supplement 1): 6892.

https://doi.org/10.1182/blood-2025-6892

Published: 2025

Journal Articles

Reducing Acute Myeloid Leukemia resistance to CAR T cell therapy by epigenetic activation of the tumor inflammasome-pyroptosis signaling

Xin Huang, Qingrong Huang, Ciril Abraham, Mimi Chen, Ying Wang, Yuanyuan Tian, Yongping Zhang, Gennaro Calendo, Jean-Pierre Issa, Yi Zhang

Blood (2025) 146 (Supplement 1): 5901.

https://doi.org/10.1182/blood-2025-5901

Published: 2025

Journal Articles

Preclinical and clinical Study of olverembatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement

Blood (2025) 146 (Supplement 1): 1979.

https://doi.org/10.1182/blood-2025-1979

Published: 2025

Journal Articles

A decisional intervention for older patients with Acute Myeloid Leukemia and their oncologist: A pilot randomized controlled trial (RCT)

Blood (2025) 146 (Supplement 1): 1081.

https://doi.org/10.1182/blood-2025-1081

Published: 2025

Journal Articles

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

Blood (2025) 146 (Supplement 1): 1574.

https://doi.org/10.1182/blood-2025-1574

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Updated results from the Phase 1b/2 study of MK-1045, a novel CD19xCD3 T-cell engager, in adult participants with relapsed or refractory B-cell acute lymphoblastic leukemia

Impact of antibiotic exposure on CAR-T cell therapy outcomes: Analysis in multiple Myeloma and lymphoma

Upfront maintenance therapy improves the prognosis of patients with diffuse large B-cell lymphoma in the era of novel agents: A multicenter retrospective study

Clinical features and outcome of Philadelphia chromosome-positive acute lymphoblastic leukemia: A 15-year retrospective study

Designing immune-evasive ucar-T cells to overcome allogeneic barriers and advance off-the-shelf immunotherapy

CTD402, allogeneic anti-CD7 CAR t-cell, in relapsed or refractory (R/R) t-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (T-ALL/LBL) - report of clinical outcomes at the recommended phase 2 dose (RP2D)

Synergistic integration of CAR-T cell pharmacokinetics and NGS-MRD evolution enables precision risk stratification in relapsed/refractory B-cell acute lymphoblastic leukemia

Mitoxantrone liposome, subcutaneous cytarabine and G-CSF (CMG) combined with venetoclax as first-line treatment in secondary Acute Myeloid Leukemia (sAML) or elderly AML patients: A multicenter, prospective, single-arm clinical trial with concurrent control

ZFP36L2 as a promising therapeutic target in acute graft-versus-host disease: Evidence from murine models and clinical validation

First-in-human phase I study of HCB101, a 3.5th-generation CD47-SIRPα fc fusion protein: Cytopenia-sparing safety, broad pharmacologic window, and low-dose clinical activity in relapsed/refractory non-Hodgkin lymphoma

CD7-targeted universal CAR T-cell therapy in relapsed or refractory (R/R) acute myeloid leukemia (AML): Clinical results from CTD401/402 studies

Enhanced vsvg variants for binder‑dependent and high‑specificity transduction of primary T cells

Droplet digital PCR outperforms conventional methods for early relapse prediction in AML/MDS patients post-transplant

Efficacy and safety profile of inaticabtagene autoleucel in Chinese patients with B-cell acute lymphoblastic leukemia: Insights from real-world data

Long-term outcomes with emicizumab prophylaxis in patients with hemophilia a in China

Neutrophil count is an independent prognostic indicator in early T-cell precursor lymphoblastic leukemia

Reducing Acute Myeloid Leukemia resistance to CAR T cell therapy by epigenetic activation of the tumor inflammasome-pyroptosis signaling

Preclinical and clinical Study of olverembatinib in patients with myeloid/lymphoid neoplasms with FGFR1 rearrangement

A decisional intervention for older patients with Acute Myeloid Leukemia and their oncologist: A pilot randomized controlled trial (RCT)

Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only